-
An increased risk of cervical cancer is associated with long durations of use of hormonal contraceptives.
-
New clinical practice guidelines for the prevention, detection, and treatment of high blood pressure recommend earlier and more aggressive intervention for control of the disease.
-
The U.S. Food and Drug Administration (FDA) and the National Cancer Institute (NCI) have recently announced that they will share knowledge and resources to facilitate the development of new cancer drugs and speed their delivery to patients.
-
In the Pipeline
-
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) provides new clinical guidelines for hypertension prevention and management.
-
Older women taking combination hormone therapy had dementia twice as often as women not taking the therapy, according to a recently published study.
-
The U.S. Food and Drug Administration (FDA) is warning pharmacists and consumers to beware of counterfeit atorvastatin calcium (Lipitor).
-
The U.S. Supreme Court has ruled that Maine can continue with its efforts to implement its Maine Rx program, which was designed primarily to provide discounted prescription drugs to Maines uninsured residents.
-
The FDA has announced two measures to inform the public about the status of manufacturers commitments to carry out further clinical studies following the FDAs approval of certain drugs and biological products.
-
Due to manufacturing problems, the U.S. Food and Drug Administration (FDA) took urokinase (Abbokinase) off the market in December 1998. During inspection of the manufacturing facility in October and November of 1998, urokinase production was found to differ from Good Manufacturing Practice regulations.
